In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 119139-23-0, name is 3,4-Di(1H-indol-3-yl)-1H-pyrrole-2,5-dione, introducing its new discovery. name: 3,4-Di(1H-indol-3-yl)-1H-pyrrole-2,5-dione
PYRIDAZINE DERIVATIVES
Disclosed are pyridazine derivatives of formula (I), which act as phosphodiesterase IV inhibitors and can be used for treating osteoporosis, tumors, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases, and AIDS.
We¡¯ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 119139-23-0, and how the biochemistry of the body works.name: 3,4-Di(1H-indol-3-yl)-1H-pyrrole-2,5-dione
Reference£º
Chiral nitrogen ligands in late transition metal-catalysed asymmetric synthesis¡ªI. Addressing the problem of ligand lability in rhodium-catalysed hydrosilations,
Nitrogen-Containing Ligands for Asymmetric Homogeneous and Heterogeneous Catalysis